-
Study aim
-
Determine the effects of N-Acetylcysteine (NAC) on senescence of visceral adipose tissue, anthropometric indices, serum levels of lipid profile, glycemic indices, and inflammatory factors in obese adults
-
Design
-
A parallel randomized block clinical trial (blocks of 4) stratified by age and body mass index, phase 3, double-blind clinical trial on 50 obese adults for 4 weeks.
-
Settings and conduct
-
This study will be conducted in the surgery and obesity clinic of Modarres Hospital on 50 obese adults. The study will be conducted in a double-blind manner with a control group. Due to the double-blindness of the study, before the start of the study, the sets of cans containing capsules will be prepared by someone other than the researcher, and the placebo will be similar in appearance to the intervention group. The intervention group will receive 600 mg N-acetylcysteine per day and the control group will receive 600 mg placebo per day for 4 weeks. At the beginning and after 4 weeks, the different effects of the intervention on these people are examined and compared.
-
Participants/Inclusion and exclusion criteria
-
People with obesity with a body mass index (BMI) greater than or equal to 30 kg/m2, Age over 25 years, Non-pregnant, Non-lactating, Not suffering from chronic and acute inflammatory, and infectious diseases, Not suffering from high blood pressure and vascular diseases, Not receiving alcohol and smoking, Not participating in other clinical trial studies at the same time as the present study, Not receiving weight loss and antioxidant drugs and supplements in the last three months.
-
Intervention groups
-
The intervention and control groups will receive 600 mg of N-acetylcysteine supplement and placebo 4 weeks before sleeve surgery, respectively.
-
Main outcome variables
-
Weight, beta-galactosidase activity, triglyceride, glucose, total cholesterol, and interleukin-6.